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orikawa S, Sone T, Tsuboi H, Mukawa H, Morishima I, Uesugi M, Morita Y, Numaguchi Y, Okumura K,
urohara T. Renal Protective Effects and the Prevention of Contrast-Induced Nephropathy by Atrial Natriuretic
eptide. J Am Coll Cardiol 2009;53:1040–6.
n this article, the 1.00 p values in Table 3 (on page 1045) are incorrect. The corrected full table is printed below. The authors
pologize for this error.
doi:10.1016/j.jacc.2009.08.004
Univariate Analysis for CINTable 3 Univariate Analysis for CIN
CIN
  Odds Ratio p Value
Age 70 yrs 73.7% 74.9% 0.95 0.91
Hypertension 78.9% 75.7% 1.20 0.75
Diabetes mellitus 57.9% 43.8% 1.76 0.24
History of myocardial infarction 47.4% 43.8% 0.87 0.77
Anemia 57.9% 67.2% 0.67 0.45
ACE inhibitors or ARBs 68.4% 66.4% 1.10 0.86
Calcium-channel blockers (alone) 15.8% 9.8% 1.73 0.42
Diuretics 52.6% 53.2% 0.98 0.96
Statins 57.9% 63.8% 1.28 0.61
LVEF 40% 15.8% 19.6% 0.77 0.69
Contrast media 155 ml 68.4 24.3% 6.77 0.001
Baseline creatinine 2.0 mg/dl 21.1% 20.9% 1.01 0.98
ANP administration 21.1% 51.9% 0.25 0.015
Anemia was defined as a hematocrit level of 39% for men or of 36% for women.
ACE  angiotensin-converting enzyme; ANP  atrial natriuretic peptide; ARB  angiotensin II receptor blocker; CIN  contrast-induced
nephropathy; LVEF  left ventricular ejection fraction.
